Multi-Modal Neuroimaging in Premanifest and Early Huntington's Disease: 18 Month Longitudinal Data from the IMAGE-HD Study

Dominguez D, Juan F., Egan, Gary F., Gray, Marcus A., Poudel, Govinda R., Churchyard, Andrew, Chua, Phyllis, Stout, Julie C. and Georgiou-Karistianis, Nellie (2013) Multi-Modal Neuroimaging in Premanifest and Early Huntington's Disease: 18 Month Longitudinal Data from the IMAGE-HD Study. PLoS ONE, 8 9: e74131.1-e74131.9. doi:10.1371/journal.pone.0074131

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ313062_fulltext.pdf Full text (open access) application/pdf 785.39KB 27

Author Dominguez D, Juan F.
Egan, Gary F.
Gray, Marcus A.
Poudel, Govinda R.
Churchyard, Andrew
Chua, Phyllis
Stout, Julie C.
Georgiou-Karistianis, Nellie
Title Multi-Modal Neuroimaging in Premanifest and Early Huntington's Disease: 18 Month Longitudinal Data from the IMAGE-HD Study
Journal name PLoS ONE   Check publisher's open access policy
ISSN 1932-6203
Publication date 2013-09
Year available 2013
Sub-type Article (original research)
DOI 10.1371/journal.pone.0074131
Open Access Status DOI
Volume 8
Issue 9
Start page e74131.1
End page e74131.9
Total pages 10
Place of publication San Francisco, CA, United States
Publisher Public Library of Science
Collection year 2014
Language eng
Formatted abstract
IMAGE-HD is an Australian based multi-modal longitudinal magnetic resonance imaging (MRI) study in premanifest and early symptomatic Huntington's disease (pre-HD and symp-HD, respectively). In this investigation we sought to determine the sensitivity of imaging methods to detect macrostructural (volume) and microstructural (diffusivity) longitudinal change in HD. We used a 3T MRI scanner to acquire T1 and diffusion weighted images at baseline and 18 months in 31 pre-HD, 31 symp-HD and 29 controls. Volume was measured across the whole brain, and volume and diffusion measures were ascertained for caudate and putamen. We observed a range of significant volumetric and, for the first time, diffusion changes over 18 months in both pre-HD and symp-HD, relative to controls, detectable at the brain-wide level (volume change in grey and white matter) and in caudate and putamen (volume and diffusivity change). Importantly, longitudinal volume change in the caudate was the only measure that discriminated between groups across all stages of disease: far from diagnosis (>15 years), close to diagnosis (<15 years) and after diagnosis. Of the two diffusion metrics (mean diffusivity, MD; fractional anisotropy, FA), only longitudinal FA change was sensitive to group differences, but only after diagnosis. These findings further confirm caudate atrophy as one of the most sensitive and early biomarkers of neurodegeneration in HD. They also highlight that different tissue properties have varying schedules in their ability to discriminate between groups along disease progression and may therefore inform biomarker selection for future therapeutic interventions.
Keyword Whole Brain Atrophy
Basal Ganglia
Clinical trials
Caudate Nucleus
Progression
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2014 Collection
Centre for Advanced Imaging Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 25 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 27 Oct 2013, 00:09:49 EST by System User on behalf of Centre for Advanced Imaging